Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults

被引：0

作者：

Raffi, Francois ^{[1
]}

Orkin, Chloe ^{[2
]}

Clarke, Amanda ^{[3
]}

Slama, Laurence ^{[4
]}

Gallant, Joel ^{[5
]}

Daar, Eric ^{[6
]}

Yan, Mingjin ^{[7
]}

Abram, Michael E. ^{[8
]}

Friborg, Sandra ^{[9
]}

Cheng, Andrew ^{[10
]}

Rhee, Martin ^{[10
]}

机构：

[1] CHU Nantes, Infect & Trop Dis, Nates, France

[2] Barts Hlth NHS Trust, Infect & Immun, London, England

[3] Brighton & Sussex Univ, Hosp NHS Trust, HIV Unit, Brighton, E Sussex, England

[4] Hop Tenon, Infect & Trop Dis, Paris, France

[5] Southwest Care Ctr, Specialty Serv, Santa Fe, NM USA

[6] Angeles Biomed Res Inst Harbor UCLA, Div Adult Infect Dis, Torrance, CA USA

[7] Gilead Sci, Biostatist HIV, Foster City, CA USA

[8] Gilead Sci, Clin Virol, Foster City, CA USA

[9] Gilead Sci, Clin Operat HIV, Foster City, CA USA

[10] Gilead Sci, Clin Res HIV, Foster City, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

O125

引用

页数：2